Characterization of scavengers of γ-ketoaldehydes that do not inhibit prostaglandin biosynthesis

Chemical Research in Toxicology

Volumn 23, Issue 1, 2010, Pages 240-250

  Zagol Ikapitte, Irene ^a   Amarnath, Venkataraman ^a   Bala, Manju ^a   Roberts II, L Jackson ^a   Oates, John A ^a   Boutaud, Olivier ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; G PROTEIN COUPLED RECEPTOR; LEVUGLANDIN E2; LIPID; LYSINE; PROSTAGLANDIN SYNTHASE; PROSTANOID;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BIOSYNTHESIS; CATALYSIS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; LIPID PEROXIDATION; MOLECULAR LIBRARY; NONHUMAN; PROTEIN FUNCTION; PROTEIN MODIFICATION; THROMBOCYTE ACTIVATION; UPREGULATION;

AMINES; BLOOD PLATELETS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; HEP G2 CELLS; HUMANS; PROSTAGLANDINS; PROSTAGLANDINS H; PYRIDOXAMINE;

ANIMALIA;

EID: 75149187560     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx900407a     Document Type: Article

References (36)

1. Wang, M. T., Honn, K. V., and Nie, D. (2007) Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 26, 525-534.
2. Cha, Y. I., and DuBois, R. N. (2007) NSAIDs and cancer prevention: targets downstream of COX-2. Annu. Rev. Med. 58, 239-252.
3. Minghetti, L. (2004) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 63, 901-910.
4. Pasinetti, G. M. (1998) Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J. Neurosci. Res. 54, 1-6.
5. Harris, R. E. (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17, 55-67.
6. Harris, R. E., Beebe-Donk, J., and Alshafie, G. A. (2007) Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell. Biochem. 42, 193-202.
7. Harris, R. E., Beebe-Donk, J., and Alshafie, G. A. (2007) Reduced risk of human lung cancer by selective cyclooxygenase 2 blockade: results of a case control study. Int. J. Biol. Sci. 3, 328-334.
8. Agrawal, A., and Fentiman, I. S. (2008) NSAIDs and breast cancer: a possible prevention and treatment strategy. Int. J. Clin. Pract. 62, 444-449.
9. Roberts, R. O., Jacobson, D. J., Girman, C. J., Rhodes, T., Lieber, M. M., and Jacobsen, S. J. (2002) A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin. Proc. 77, 219-225.
10. Rostom, A., Dube, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., and Moher, D. (2007) Nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann. Intern. Med. 146, 376-389.
11. Stewart, W. F., Kawas, C., Corrada, M., and Metter, E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632.
12. in t' Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. and, and Stricker, B. H. 2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's diseaseN. Engl. J. Med. 345, 1515-1521.
13. Salomon, R. G. (1985) Prostaglandin endoperoxide reaction mechanisms and the discovery of levuglandins. Acc. Chem. Res. 18, 294-301.
14. Iyer, R. S., Kobierski, M. E., and Salomon, R. G. (1994) Generation of pyrroles in the reaction of levuglandin E2 with proteins. J. Org. Chem. 59, 6038-6043.
15. Brame, C. J., Salomon, R. G., Morrow, J. D., and Roberts, L. J. (1999) Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J. Biol. Chem. 274, 13139-13146.
16. Boutaud, O., Brame, C. J., Salomon, R. G., Roberts, L. J., II, and and Oates, J. A. (1999) Characterization of the lysyl adducts formed from prostaglandin H2 via the levuglandin pathway. Biochemistry 38, 9389-9396.
17. Zagol-Ikapitte, I., Bernoud-Hubac, N., Amarnath, V., Roberts, L. J., II, Boutaud, O., and Oates, J. A. (2004) Characterization of bis(levuglandinyl) urea derivatives as products of the reaction between prostaglandin H(2) and arginine. Biochemistry 43, 5503-5510.
18. Davies, S. S., Amarnath, V. and, and Roberts, L. J., 2nd. (2004) Isoketals: highly reactive gamma-ketoaldehydes formed from the H2-isoprostane pathway. Chem. Phys. Lipids 128, 85-99.
19. Boutaud, O., Li, J., Zagol, I., Shipp, E. A., Davies, S. S., Roberts, L. J., 2nd, and Oates, J. A. (2003) Levuglandinyl adducts of proteins are formed via a prostaglandin H2 synthase-dependent pathway after platelet activation. J. Biol. Chem. 278, 16926-16928.
20. Boutaud, O., Andreasson, K. I., Zagol-Ikapitte, I., and Oates, J. A. (2005) Cyclooxygenase-dependent lipid-modification of brain proteins. Brain Pathol. 15, 139-142.
21. Zagol-Ikapitte, I., Masterson, T. S., Amarnath, V., Montine, T. J., Andreasson, K. I., Boutaud, O., and Oates, J. A. (2005) Prostaglandin H-derived adducts of proteins correlate with Alzheimer's disease severity. J. Neurochem. 94, 1140-1145.
22. 1-42 oligomers. J. Neurochem. 82, 1003-1006.
23. Boutaud, O., Montine, T. J., Chang, L., Klein, W. L., and Oates, J. A. (2006) PGH-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. J. Neurochem. 96, 917-923.
24. Amarnath, V., Amarnath, K., Davies, S., and Roberts, L. J., II. (2004) Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls. Chem. Res. Toxicol. 17, 410-415.
25. Davies, S. S., Brantley, E. J., Voziyan, P. A., Amarnath, V., Zagol-Ikapitte, I., Boutaud, O., Hudson, B. G., Oates, J. A., and Ii, L. J. (2006) Pyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against H(2)O(2)-mediated cytotoxicity. Biochemistry 45, 15756-15767.
26. Marnett, L. J., Siedlik, P. H., Ochs, R. C., Pagels, W. R., Das, M., Honn, K. V., Warnock, R. H., Tainer, B. E., and Eling, T. E. (1984) Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom. Mol. Pharmacol. 26, 328-335.
27. Marnett, L. J., Rowlinson, S. W., Goodwin, D. C., Kalgutkar, A. S., and Lanzo, C. A. (1999) Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem. 274, 22903-22906.
28. Wu, Y. K., and Ahlberg, P. (1989) On the formation of isopropylidenepyridoxines. A convenient method for the preparation of 2,2,8-trimethyl-4H-1,3-dioxino[4,5-c]pyridin-5-ylmethanol from pyridoxine hydrochloride. Acta Chem. Scand. 43, 1009-1011.
29. Yang, D., Shih, Y., and Liu, H. (1991) Chemical synthesis of stereospecifically labeled pyridoxamine 5′-phosphate. J. Org. Chem. 56, 2940-2946.
30. Hofslokken, N. U., and Skattebol, L. (1999) Convenient method for the ortho-formylation of phenols. Acta Chem. Scand. 53, 258-262.
31. Boutaud, O., Aronoff, D. M., Richardson, J. H., Marnett, L. J., and Oates, J. A. (2002) Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases. Proc. Natl. Acad. Sci. U.S.A. 99, 7130-7135.
32. Crouch, S. P., Kozlowski, R., Slater, K. J., and Fletcher, J. (1993) The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J. Immunol. Methods 160, 81-88.
33. Doorn, J. A., and Petersen, D. R. (2002) Covalent modification of amino acid nucleophiles by the lipid peroxidation products 4-hydroxy-2-nonenal and 4-oxo-2-nonenal. Chem. Res. Toxicol. 15, 1445-1450.
34. Liu, Z., Minkler, P. E., and Sayre, L. M. (2003) Mass spectroscopic characterization of protein modification by 4-hydroxy-2-(E)-nonenal and 4-oxo-2-(E)-nonenal. Chem. Res. Toxicol. 16, 901-911.
35. Cree, I. A., and Andreotti, P. E. (1997) Measurement of cytotoxicity by ATP - based luminescence assay in primary cell cultures and cell lines. Toxicol. In Vitro 11, 553-556.
36. Mitchell, J. A., Larkin, S., and Williams, T. J. (1995) Cyclooxygenase-2: regulation and relevance in inflammation. Biochem. Pharmacol. 50, 1535-1542.